Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$12.77 USD
-0.41 (-3.11%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $12.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Day One Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 206 | 147 | 73 | 14 | 15 |
Income After Depreciation & Amortization | -206 | -147 | -73 | -14 | -15 |
Non-Operating Income | 17 | 0 | 0 | -30 | 0 |
Interest Expense | 0 | -5 | 0 | 0 | 2 |
Pretax Income | -189 | -142 | -73 | -44 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | -2 | -3 | -4 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -189 | -142 | -73 | -44 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -189 | -142 | -71 | -41 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -206 | -146 | -73 | -14 | -15 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -206 | -147 | -73 | -14 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 79.77 | 65.47 | 36.96 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.37 | -2.17 | -4.62 | NA | NA |
Diluted Net EPS (GAAP) | -2.37 | -2.17 | -4.62 | -7.33 | NA |
Fiscal Year end for Day One Biopharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 66.77 | 59.52 | 51.44 | 49.25 | 45.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | -66.77 | -59.52 | -51.44 | -49.25 | -45.86 |
Non-Operating Income | 4.36 | 5.01 | 5.29 | 3.39 | 3.46 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -62.41 | -54.51 | -46.15 | -45.86 | -42.39 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -62.41 | -54.51 | -46.15 | -45.86 | -42.39 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -62.41 | -54.51 | -46.15 | -45.86 | -42.39 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 86.68 | 79.77 | 85.95 | 74.97 | 71.97 |
Diluted EPS Before Non-Recurring Items | -0.72 | -0.64 | -0.54 | -0.61 | -0.59 |
Diluted Net EPS (GAAP) | -0.72 | -0.63 | -0.54 | -0.61 | -0.59 |